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Introduction
Rheumatoid Arthritis (RA) is a chronic inflammatory 
autoimmune disease affecting about 1% of the human population and 
is associated with inflammation and destruction of distal joints [1,2]. 
The etiology is unclear; however, genetic susceptibility, environmental 
influences, and microbial infections have been implicated in causing 
the disease [3]. Glucose-6-Phosphate Isomerase (GPI) is one of the 
autoantigens against which RA patients develop autoantibodies 
that have been found to circulate in serum and in synovial fluid of 
these patients [4-6]. The major histological characteristics of human 
RA, such as leukocyte invasion, synovitis, pannus formation, and 
cartilage and bone destruction have been observed in the K/BxN 
mouse model as well [7]. In addition, the K/BxN mouse disease 
shares other immunological abnormalities with human RA including 
cytokine imbalances, B-cell activation, and autoantibody production 
[8,9]. Like in humans, GPI was found deposited on the cartilage 
surface of normal mice, and also in high quantities of arthritic mice 
[10]. Purified GPI polyclonal IgG antibodies localize specifically to 
distal joints within minutes after intravenous injection and remain 
localized for at least 24 h [11]. Of note, arthritis-like symptoms 
were observed to develop in naive Balb/c mice by the transfer of 
polyclonal GPI antibodies or by transferring at least two different 
monoclonal GPI-specific antibodies [11,12]. In the K/BxN mouse, 
disease onset can be triggered by simultaneously administering the 
two pathogenic GPI-specific monoclonal antibodies 11H3 and 46H9 
[13]. GPI-antibody complexes on joint cartilage surfaces have been 
shown to initiate an inflammatory cascade through the alternative 
complement pathway [10].
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Abstract
Rheumatoid arthritis-like symptoms can be initiated experimentally in naive K/BxN mice by simultaneously 
administering the two monoclonal antibodies 11H3 and 46H9. Both antibodies specifically recognize Glucose-
6-Phosphate Isomerase (GPI), a known auto antigen in RA patients. Amino acid sequences of the Fv parts of
the antibodies were determined by translating the respective hybridoma DNA sequences and served for three-
dimensional structure modeling of the paratope regions. In silico docking of both Fv antibody structure models to
the X-ray structures of the homodimeric murine GPI as well as to the homodimeric human GPI predicted the murine
epitope of the 11H3 antibodies to comprise partial amino acid sequences QRVRSGDWKGYTGKS (aa134-148) and
AAKDPSAVAK (aa232-241), generating an assembled (conformational) epitope. The 11H3 epitope on human GPI
encompasses the matching partial amino acid sequences QRVRSGDWKGYTGKT (aa134-148) and AAKDPSAVAK
(aa232-241). The epitope of the 46H9 antibody was determined to consist of the partial murine GPI amino acid
sequence RKELQAAGKSPEDLEK (aa446-461) and the human GPI amino acid sequence RKELQAAGKSPEDLER
(aa446-461), respectively, resembling consecutive (linear) epitopes. The predicted epitopes were verified by mass
spectrometric epitope mapping using synthetic epitope peptides. Peptide QRVRSGDWKGYTGKS[GSMSGS]
AAKDPSAAK included a small spacer sequence in between the epitope sequences, mimicking the assembled
epitope for the 11H3 antibody. The peptide RKELQAAGKSPEDLEK represented the consecutive epitope for the
46H9 antibody. The determined B-cell epitopes of GPI and their interactions with the monoclonal antibodies provide
a detailed structural understanding of immunological disease onset mechanisms in a mouse model of rheumatoid
arthritis.
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Correctly predicting an antibody’s B-cell epitope is essential 
for many aspects of immunological understanding and clinical 
applications, including elucidating the molecular basis of immunity 
and autoimmunity, designing immunogens that stimulate antibody 
production for vaccine and therapeutic development [14,15], predicting 
cross-reactivity [15], and designing immunodiagnostic agents [16]. 
Subsequently, it is relevant to determine autoantigen-autoantibody 
interactions at the molecular level, and particularly to identify the 
epitopes to which the GPI-specific monoclonal antibodies 11H3 and 
46H9 bind on either murine GPI or human GPI.
Epitope mapping is the process of identifying individual amino 
acid residues of the (auto)antigen involved in binding with the amino 
acid residues of the (auto)antibody paratope [17]. Epitope mapping 
approaches can be broadly classified as either structural (X-ray 
crystallography, nuclear magnetic resonance, and electron microscopy) 
or functional (competition assays, antigen modification, antigen 
fragmentation and synthetic peptides) [18]. Many of the functional 
approaches are performed in conjunction with mass spectrometry 
(recently reviewed in Opuni et al. [19]), and the most commonly used 
mass spectrometry-based epitope mapping approaches are epitope 
excision [20] and epitope extraction [21]. However, most of the 
experimental epitope mapping approaches are costly, time-consuming, 
and sometimes not viable since some antigens are insoluble in non-
denaturing buffer solutions. Hence, in silico epitope prediction is a 
potentially useful alternative for epitope characterization on (auto) 
antigens towards specific (auto) antibodies [22,23].
Numerous computational tools have shown promise for reliable 
epitope prediction and have been reviewed extensively [16,24-32]. 
Among this list of computational tools, Molecular Dynamics (MD) 
simulations are particularly useful for structure-based epitope 
prediction that exploits not only static tertiary structural information 
about the relevant antibody and antigen, but also the time-dependent 
dynamical and conformational properties of both proteins and their 
predicted thermodynamic interaction energies. Consequently, MD 
simulations have been widely used for predicting B-cell epitopes [33-
35]. Given the strengths and limitations of experimental methods 
and computational methods, in the present study we combine mass 
spectrometry and MD simulations in order to predict epitope regions 
of glucose-6-phosphate isomerase. We applied a set of in silico methods, 
including molecular modeling, docking, and MD simulations of X-ray 
structures of the autoantigens and of modeled Fv structures of the 
monoclonal antibodies 11H3 and 46H9. The predicted epitopes were 
confirmed experimentally by mass spectrometric epitope extraction 
using chemically synthesized epitope peptides.
Materials and Methods
Generation of GPI specific monoclonal antibodies 11H3 and 
46H9
Mice were from own breeding at the animal center of the University 
of Konstanz where they were kept by veterinaries and with allowance 
from the authorities (Regierungspräsidium Freiburg). At the time 
of hybridoma generation extraction of organs from mice was done 
upon legal notification to the Regierungspräsidium Freiburg (formal 
notice, register no.: O-00/24). Formal allowance was not required as 
was confirmed by official notice (formal waiver of ethical approval, file 
number: 35-9185.5/414). The number of sacrificed mice was five. They 
were killed by cervical dislocation. 
For the production of GPI specific monoclonal antibodies, one 
week prior to fusion SP2/0 myeloma fusion partner cells were expanded 
in Iscoves medium with 10% FCS. 96-well plates were plated with 
peritoneal cells obtained from C57BL/6 mice and the K/BxN mice were 
immunized with purified recombinant GPI after removal of Glutathione 
S-transferase (GST) tag. The recombinant GPI was expressed and 
purified as previously described [36]. On day of fusion, mice were 
sacrificed; spleens were harvested and teased to obtain single cell 
suspensions. Debris was removed by passage through a fine steel mesh, 
and washed cells were suspended in serum-free Iscoves media. The 
spleen cells were mixed in a 1:1 ratio with SP2/0 cells in 50 mL conical 
centrifuge tubes, pelleted at 500 g and the supernatants were discarded. 
Cell fusion was performed in a laminar hood with the cell pellets in a 
water bath at 37°C. To each cell suspension 1 mL pre-warmed 50% PEG 
solution was added drop-by-drop over 1 min while stirring after each 
drop. This process was repeated with an additional 1 mL of pre-warmed 
serum-free Iscoves medium. A further 7 mL of pre-warmed serum free 
Iscoves medium was added drop-by-drop over 2-3 min. The fusion 
mixes were pelleted at 500 g for 5 min at RT and the supernatants were 
discarded. Placing the cell pellets at 37°C, 10 mL of pre-warmed Iscoves 
medium with 20% FCS was forcibly added to disrupt the cell pellets and 
the volumes were adjusted to reach final cell densities of 2.5 × 106 cells/
mL. Cell suspensions were then gently pipetted out at 100-125 cells/
well into 96-well flat bottom plates with feeder cells and incubated in 
5% carbon dioxide (CO2) at 37°C. On days 2, 3, 4, 5, 7, 9, and 11, half 
the volumes of each well were aspirated using sterile Pasteur pipettes 
attached to a vacuum pump and 2 drops of Iscoves medium with 20% 
FCS and 1x HAT (hypoxanthine-aminopterin-thymidine), each, were 
added. On day 14 the feeding was done with Iscoves medium with 20% 
FCS and 1x HT (hypoxanthine-thymidine). From day 15 onward, the 
cells were fed with Iscoves medium with 20% FCS. The hybridomas 
were screened when the cells showed 10-25% confluence. About 100 µL 
supernatant from each well were removed and tested for GPI reactivity 
by GPI ELISA as previously described [36].
Next, limiting dilution cloning of hybridomas and adaption to 
serum-free media was performed. Briefly, 10 days prior to cloning, 96-
well plates were plated with peritoneal cells obtained from C57BL/6 
mice and grown at 37°C. On the day of cloning, hybridoma cells were 
counted and examined for viability by trypan blue dye exclusion stain. 
The viability was at least 80% for successful cloning. For each hybridoma, 
the cells were serially diluted in Iscoves medium with 20% FCS to give 4, 
2, and 1 cells/mL. The diluted cells were then plated with 250 µL/well for 
each dilution in prepared 96-well plates. Cells were incubated at 37°C 
in 7.5% CO2 for 5-7 days. The plates were microscopically examined for 
plating and cloning efficiency. Wells with single clones were analyzed 
for GPI reactivity using ELISA, and positive clones were expanded for 
freezing. The hybridomas were adapted to grow in serum-free media 
(SFM) to reduce protein loads in downstream processing. Hybridomas 
were grown in Iscoves medium with 10% FCS. The growing cells were 
then serially expanded in Iscoves medium with 10% FCS with 25% 
SFM followed by 50% SFM medium and finally in complete 100% SFM 
media.
DNA sequencing of GPI specific monoclonal antibodies 11H3 
and 46H9
The total RNA extraction of 46H9 and 11H3 hybridoma cells 
was performed using the mi-Total RNA Isolation Kit (Metabion, 
Martinsried, Germany). cDNA synthesis was done using the Revert 
Aid First Stand cDNA Synthesis Kit (Thermo Scientific, Karlsruhe, 
Germany). For amplification of the V regions degenerated primers, 
binding to the leader sequences of the V regions and primers binding 
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to the constant region of IgG1 and kappa were used (primers and 
sequences are shown in Supplemental Table 1). For each hybridoma cell 
line ten PCR reactions were set up, six reactions for the amplification 
of light chain V regions and four reactions for the amplification of the 
heavy chain V regions. For each PCR reaction 2 µL from the cDNA 
synthesis reactions were used (PCR conditions for V region isolation are 
shown in Supplemental Table 2). Amplified DNA was extracted using 
the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) and DNA 
ligation was performed using the InsTAclone PCR Cloning Kit (Thermo 
Scientific, Karlsruhe, Germany). The analysis of the recombinant clones 
was performed using colony PCR primers (Supplemental Table 3). For 
the colony PCR, white clones from the transformation were marked 
and tipped using a sterile pipette and re-suspended in PCR master mix 
containing 100 pmol of M13-forward and-reverse primer (Colony PCR 
conditions are shown in Supplemental Table 4).
Plasmids from bacterial colonies were isolated using the 
GeneElute HP Plasmid Miniprep kit (Sigma-Aldrich, München, 
Germany). Sequencing of V regions was done by gatc (http://www.
gatc.org, Konstanz, Germany) using T7 primers. The sequences were 
characterized and analyzed using the Immunogenetics Database 
(http://imgt.org) [37].
Modeling of the 3D structures of the variable region fragments 
of GPI-specific monoclonal antibodies and atomic structure 
coordinates of Glucose-6-Phosphate Isomerase (GPI)
The amino acid sequences of the light chains and heavy chains of 
the variable region fragments (Fv) of the GPI-specific antibody 11H3, 
which had been translated from the DNA sequences, were used for 
modeling of the antibody structure. The antibody Fv structure was 
predicted using the freely available Rosetta Antibody server (http://
rosie.rosettacommons.org/antibody) [38,39]. The “model H3 loop” 
option was selected. The server generated PDB files of 2048 candidate 
Fv structures and their energy values. The Fv structure of the GPI-
specific antibody 11H3 possessing the minimum energy value was 
selected as our working structure. This procedure was also performed 
using amino acid sequences of the light chains and heavy chains of 
the variable region fragments (Fv) of the GPI-specific antibody 46H9, 
which had been translated from the DNA sequences. Fv structures 
were visualized using the UCSF Chimera (http://www.cgl.ucsf.edu/
chimera/) molecular visualization software [40].
The coordinates of all non-hydrogen atoms of the dimeric 
structures of murine glucose-6-phosphate isomerase (PDB ID 2CVP) 
and of human glucose-6-phosphate isomerase (PDB ID 1IRI) were 
downloaded from the RCSB Protein Data Bank (www.rcsb.org).
Docking experiments between GPI and GPI-specific 
monoclonal antibodies, inter-epitope model comparison, 
and buried surface area (BSA) calculations
Docking experiments were performed for the murine GPI antigen-
11H3 antibody pair using the Fv structure of 11H3 antibody and the 
X-ray structure of the murine GPI antigen in conjunction with the 
antibody-modeling feature of the ClusPro 2.0 server (http://cluspro.
bu.edu/login.php) [41,42]. Next, the Chimera software was used to 
perform atom-to-atom contact analyses between murine GPI antigen 
and amino acids in the paratope region of 11H3 for all the docked 
murine GPI antigen-11H3 antibody structures using a contact distance 
of ≤4 Å. The amino acid sequence of the murine GPI that formed 
contacts with the 11H3 paratope region were considered as epitope 
models [17]. The above procedure was identically performed for the 
human GPI antigen-11H3 antibody pair, the murine GPI antigen-46H9 
antibody pair, and the human GPI antigen-46H9 antibody pair.
An inter-epitope model comparison was performed for the 11H3 
antibody docked to either murine or human GPI antigen. First, 
the amino acid sequence position of the predicted epitope of 11H3 
antibody on murine GPI from all the epitope models of murine GPI 
antigen-11H3 antibody pair was compared with that of human GPI 
antigen-11H3 antibody pair. Next, amino acid residue similarity of 
the matching sequence position of epitope models from murine GPI 
antigen-11H3 antibody pair was compared with the respective epitope 
model from human GPI antigen-11H3 antibody pair. Epitope model 
pairs that shared both high sequence position and amino acid identity 
were considered as potential candidates for epitope identification. This 
procedure was identically performed for the 46H9 antibodies docked to 
either murine or human GPI.
The EpiMED-Surf bioinformatics tool [43] was used to calculate 
the Buried Surface Area (BSA) upon antibody binding to the murine 
GPI epitope surfaces for the docked antigen-antibody complex. The 
“calculate electrostatics” and “calculate hydrophobicity and ASA 
(accessible surface area)” options were selected. BSA was calculated 
by summing the atomic surface values of all atoms of the amino acid 
residues that were part of the predicted epitope region on murine GPI 
antigen docked to 11H3 antibody. BSAs were also calculated for the 
predicted epitope regions on murine GPI antigen docked to 46H9 
antibody.
Molecular dynamics (MD) simulations of 3D structures of 
the immune complexes and clustering of MD simulations 
trajectory
The atomic coordinates of the docked structure for the murine 
GPI antigen-11H3 antibody pair were used for MD simulations using 
the GROMACS v. 4.6.7 software package [44], running on the Hyak 
cluster of computers at University of Washington, Seattle (http://
www.engr.washington.edu/mycoe/computing/facultyresources.html) 
and on local computers. MD simulations were performed using the 
AMBER99-ILDN force field [45]. The initial structure was minimized 
in vacuo using a steepest-descent algorithm to relieve unfavorable 
contacts and was subsequently solvated in a dodecahedral box of TIP3P 
water molecules [46] such that a minimum distance of 1.0 nm was 
maintained between any protein atom and the edges of the box. System 
charge neutrality was maintained by assigning seven chloride ions to 
randomly selected positions in the box. The solvated system was then 
subjected to 5000 steps of steepest-descent energy minimization using 
cutoff values of 1.0 nm for electrostatic interactions and van der Waals 
interactions.
Equilibration of the system was next carried out by performing a 
1.0-ns molecular dynamics simulation of the minimized solvated system 
in the NVT (constant number of particles, volume and temperature) 
ensemble in which the temperature was gradually raised from 200 K to 
298 K (25°C) using the Berendsen thermostat [47]. Periodic boundary 
conditions were modeled using the Particle Mesh Ewald method [48], 
and cutoff values of 1.0 nm were used for electrostatic interactions and 
van der Waals interactions. Position restraints with a force constant 
of 1000 kJ/mol/nm2 were placed on all non-hydrogen protein atoms, 
and covalent bonds were constrained using the LINCS algorithm [49]. 
A second equilibration simulation of length 1.0 ns was subsequently 
performed in the NPT (constant number of particles, pressure and 
temperature) ensemble at 298 K and at 1 atom pressure, applying the 
Berendsen coupling scheme. The final atomic velocities and positions 
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from the NVT trajectory were used as input. The same position 
restraints as used previously were applied to non-hydrogen protein 
atoms. A subsequent 5.0-ns simulation was performed at 298 K in the 
NPT ensemble in which no position restraints were applied.
Following equilibration, production molecular dynamics 
simulations were performed in triplicate for 50 ns each using different 
initial velocities in each simulation. This procedure was identically 
performed for the murine GPI antigen-46H9 antibody complex and for 
unbound murine GPI antigen using the previously generated structure 
of the murine GPI antigen-46H9 antibody complex and the murine 
GPI antigen crystal structure, respectively, as input structures.
Structures from equally spaced snapshots over the last 15 ns of all 
production molecular dynamics simulations trajectories for all modeled 
antigen-antibody complexes were clustered using the “g_cluster_mpi” 
utility of the GROMACS software. Clusters were assigned using (root 
mean squared deviation) RMSD cutoff of 0.1 nm as a metric.
Prediction of changes in binding energies of antigen-antibody 
complexes due to point mutations
The BeAtMuSiC web server (http://babylone.ulb.ac.be/beatmusic/
query.php) [50] was used for predicting changes in binding energies 
of the docked murine GPI antigen-11H3 antibody complex upon 
introducing point mutations in the antigen-antibody binding interface. 
A representative structure of the most highly populated cluster from 
the MD trajectories of the murine GPI antigen-11H3 antibody complex 
served as the analysis structure. The murine GPI antigen and 11H3 
antibody were selected as the two binding partners and the server 
automatically performed systematic mutations of interface residues. 
This procedure was likewise performed for the docked murine GPI 
antigen-46H9 antibody complex using a structure representative of 
the most highly populated cluster from the murine GPI antigen-46H9 
antibody simulation trajectories.
Western blot analyses of full-length GPI antigens
Murine GST-GPI fusion protein solution (1.43 µL; 1.39 µg/µL) 
or human GPI protein solution (4.4 µL; 0.45 µg/µL) were incubated 
with SDS sample buffer (2.5 µL; 312.5 mM TRIS/HCl pH 6.8, 10% 
SDS, 4% bromophenol blue, 50% glycerol, 325 mM DTT) at 95°C 
for 5 min. Both mixtures were loaded onto a NuPAGE Novex 10% 
Bis-TRIS gel in separate pockets. 6 µL of the PageRuler Prestained 
Protein Ladder (Thermo Scientific, USA) was also loaded onto the 
gel and functioned as an apparent molecular mass standard. The gel 
was placed in an Xcell SurelockTM Minicell electrophoresis chamber. 
500 mL of 3-(N-morpholino)propanesulfonic acid (MOPS) buffer (50 
mM MOPS, 50 mM Tris, 3.5 mM SDS, 1.0 mM EDTA) was used as 
running buffer. The gel was allowed to run for 45 min at a constant 
voltage of 200 V. The separated protein bands were then blotted onto 
a PVDF membrane (Immobilon, Millipore, Schwalbach, Germany) 
for 60 min at a constant current of 1.2 mA/cm2. The PVDF membrane 
was subsequently incubated with 10 mL blocking buffer (1:1 mixture 
of Odyssey blocking buffer (LI-COR, Nebraska, USA) and 10 mM 
PBS) for 60 min at RT. The membrane was incubated with the primary 
antibody, 11H3 monoclonal antibody, in 1:1000 dilutions (10 µL 
11H3 monoclonal antibody in 10 mL blocking buffer/0.1% Tween 20) 
overnight in a cold dark room. The membrane was washed 4 times (5 
min each) with 10 mL wash buffer (10 mM PBS, 0.1% Tween 20). The 
PDVF membrane was further incubated with the secondary antibody, 
IRDye 800 CW conjugated Goat Anti Mouse (LI-COR, Nebraska, 
USA), in 1:10,000 dilutions (1 µL IRDye 800CW conjugated Goat 
Anti Mouse in 10 mL blocking buffer/0.1% Tween 20) for 60 min at 
RT. The membrane was washed 4 times (5 min each) with 10 mL wash 
buffer and was rinsed with 10 mM PBS buffer afterwards. Detection 
was performed using an Odyssey Infrared Imaging System (LI-COR, 
Nebraska, USA). This procedure was applied with a second gel/blot 
using the 46H9 monoclonal antibody as the primary antibody with the 
following modifications: 1:1000 dilutions of the primary antibody and 
1:50,000 dilution of the secondary antibody.
Epitope extraction
The peptide with amino acid sequence 
QRVRSGDWKGYTGKS[GSMSGS]AAKDPSAK to mimic the 11H3 
antibody epitope and the peptide RKELQAAGKSPEDLEK of the 46H9 
antibody epitope were obtained as lyophilized powders (Peptides and 
Elephants GmbH, Potsdam, Germany). These peptides were dissolved 
in 10 mM PBS buffer, pH 7.4, with a final concentration of 500 μM and 
stored at -20°C. Peptide mixture I consisted of the 11H3 epitope peptide 
(315 pmol), human ACTH clip (18-39) (20 pmol; Sigma-Aldrich, Saint 
Louis, USA), and oxidized Insulin B chain (100 pmol; Sigma-Aldrich, 
Saint Louis, USA), dissolved in 50 µL of 10 mM PBS buffer, pH 7.4. 
Peptide mixture II was prepared from 20 pmol of the 46H9 epitope 
peptide and peptide standard (2 pmol, consisting of Angiotensin II, 
Angiotensin I, Substance P, Bombesin, ACTH clip (18-39), Bruker 
Daltonik, Bremen, Germany); dissolved in 50 µL 10 mM PBS buffer 7.4.
Epitope extraction [51] was performed using a programmable 
Rainin E4 XLS eight-channel electronic pipette (Mettler Toledo, 
Germany), equipped with 200 µL Pure Speed Protein Tips that contained 
5 µL of protein G resin (Mettler Toledo, Germany). Equilibration of the 
Pure Speed Protein Tips was done with 100 µL equilibration buffer (100 
mM sodium dihydrogen phosphate, 140 mM sodium chloride, pH 7.5). 
Then, 50 µL of 0.63 pmol/µL 11H3 monoclonal antibody (32 pmol) was 
applied in one tip and the GPI-specific 46H9 monoclonal antibody (50 
µL of 0.2 pmol/µL) was applied in a second tip as a control in parallel. 
For immobilization of the antibodies on the protein G resins antibody 
solutions were aspirated and dispensed in six cycles for 15 min. Next, 
excess of unbound antibodies was removed by washing with 50 µL of 
10 mM PBS buffer using six cycles of aspiration/dispension for 10 min. 
50 µL of peptide mixture I (see above) was allowed to interact with 
the immobilized antibodies for 60 min using six cycles of aspiration/
dispension, each. Non-specifically bound peptides were sequentially 
washed-off using four washing steps (three aspiration/dispension cycles 
each) with 100 µL each of wash buffer 1 (10 mM sodium dihydrogen 
phosphate, 140 mM sodium chloride in water, pH 7.5), wash buffer 2 
(140 mM sodium chloride in water, pH 7.0), wash buffer 3 (14 mM 
sodium chloride in water, pH 7.0), and wash buffer 4 (0.3 mM TRIS/
HCl, 0.25 mM n-octyl-β-D-glucopyranoside), respectively. The still 
bound (epitope) peptides were then eluted with 20 µL of elution buffer 
(3 mM hydrochloric acid, pH 2.0). The eluted peptides were subjected 
to MALDI-ToF MS analysis. The above procedure was also used for 
epitope mapping of 46H9 antibody with the following adjustments: 
200 µL Pure Speed Protein Tips that contained 5 µL of protein A resin; 
50 µL each of GPI-specific 46H9 monoclonal antibody (0.2 pmol/µL) 
was applied in one tip and GPI-specific 11H3 monoclonal antibody 
(0.63 pmol/µL) was applied in parallel in a second tip as a control; and 
50 µL of peptide mixture II (see above) was allowed to interact with 
the immobilized antibodies for 60 min using six cycles of aspiration/
dispension, each.
MALDI-ToF MS analysis
The epitope peptide containing solutions from the epitope 
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extraction experiments (10 µL each) were desalted using ZipTip 
C18 tips (Millipore, Billerica, USA) according to the manufacturer´s 
instructions [51]. The eluted samples (0.5 μL, each) were spotted onto 
an AnchorChipTM 600/384 target plate (Bruker Daltonik, Bremen, 
Germany). 2.0 μL of 2,5-dihydroxybenzoic acid (DHB, LaserBio Labs, 
France) matrix solution (5 mg DHB dissolved in 1000 μL of 50% 
acetonitrile (ACN)/0.1% TFA)) was added and mixed on the target. 
Spots were air dried at room temperature. The target was then inserted 
into the SCOUT source of the Reflex III MALDI-ToF MS instrument 
(Bruker Daltonik) [52]. Measurements were performed with the 
following instrumental settings; nitrogen laser wavelength, 337 nm; 
nitrogen laser pulse width, 3-5 ns; reflector mode acceleration voltage, 
23.0 kV. Data acquisition was performed using positive ion reflector 
mode (~100 shots per spectrum) in the mass range of m/z 1000-4000. 
The instrument was calibrated externally using a standard peptide 
mixture [53]. Data were acquired and processed using the FlexAnalysis 
2.4 and BioTools 3.0 programs (Bruker Daltonik).
Results
Modeling of 3D structures of the Fv parts of monoclonal anti-GPI 
antibodies
Our in silico epitope prediction started with generating 3D 
structures of the Fv part of the 11H3 mono-clonal antibody using 
amino acid sequences of the variable regions of the heavy and light 
chains, respectively (Supplemental Figure 1).
Amino acid sequences were obtained by translation of the 
hybridoma DNA sequences. The Complementarity Determining 
Region (CDR) H3 was modeled de novo while comparative modeling 
was used for the canonical conformations of the other CDRs. Proper 
orientation of VL-VH rigid-body and CDR backbone as well as side-
chain conformation was ensured by energy minimization using a 
50-cycle Monte Carlo minimization procedure [54].
The secondary structure elements of the Fv structure were 
antiparallel β-strands as structural scaffolds and loops in which the 
CDRs were located. The latter were assigned using the Chothia rule 
[55]. This procedure was identically performed to generate the three-
dimensional 46H9 antibody Fv structure (Supplemental Figure 1). 
Detailed antibody server modeling parameters have been published 
[39,56]. Only the Fv structure with the lowest energy was used for 
the docking analysis since it represents the most native state of the 
predicted structure.
Prediction of GPI epitopes by in silico molecular docking
For modeling the interaction site of the complex consisting of the 
murine GPI antigen and the 11H3 monoclonal antibody, we used the 
PDB file for the antigen (PDB ID: 2CVP) as well as that for the antibody 
Fv part (see above) and subjected them to rigid body in silico docking 
using the ClusPro 2.0 server. The docking was performed using the 
antibody mode of the ClusPro 2.0 server, which is based on asymmetric 
statistical potentials [57]. Twenty-nine murine GPI-11H3 antibody 
complex structures were generated, together with their weighted scores 
by which they were ranked. The first ten murine GPI-11H3 antibody 
complex structures were shortlisted and the amino acid residues of the 
murine GPI antigen that made contact with the paratope amino acid 
residues of the 11H3 antibodies were considered as epitope models 
(Table 1).
All epitope models consisted of mainly continuous stretches of 
partial amino acid sequences. In epitope model 10, the partial sequence 
417RKGL420 was flanked with residues from somewhat more distant 
sequence positions (e.g. 423K). These residues were located on one and 
the same of the two murine GPI chains (in this example on chain A 
from the homodimer). Almost all suggested epitope models also 
included parts from the other chain of the murine GPI homodimer. In 
epitope model 10, for instance, the participating amino acid residues 
on the B chain of murine GPI were 227E 529LEGSS 550K 553RD 556K. Since 
the GPI antigen is a homodimer, antibody binding was in three cases 
mirrored on “inverse” chains. Epitope models 10 and 11, for example, 
Epitope model Chain Epitope motifa SA [Å2]b
10
A 417RKGL 423K 415.21
B 227E 529LEGSS 550K 553RD 556K 886.15
11
A 527PE 530EGSSA 536T 550K 553RD 556K 1087.83
B 417RKGL 423K 402.94
12
A 89K 92YTEDR 114DGK 366K 513W 900.72
B 446R 450QAAGKSPEDLEKL 1206.94
13
A 448E 450QA 453GKS 458D 461KL 723.64
B 89K 93TEDR 114DGK 211KT 214T 216Q 248TNT 252K 255E 267WD 519KQ 524K 1787.02
14
A - -
B 134QR 140D 142KGYTGK 202E 232AAKDPSA 241K 254K 1377.97
15
A 134QR 138S 140DWKGYTGKS 237S 240AK 261Q 1171.33
B - -
16
A 135R 141WK 144YTG 234KDPSA 241K 254K 259D 261Q 1248.04
B - -
17
A 130K 134QR 137RSGD 142K 145TGKS 176KGG 180R 291D 1419.87
B 197A 87.24
18
A 89K 95D 114D 116K 212T 214T 249N 251AK 520Q 524K 953.27
B 448E 450QAAGKS 457ED 466K 770.32
19
A 112KVDGKDV 120PE 124R 248T 250TA 254K 265EFW 1225.91
B - -
aDistance between epitope and paratope amino acid groups ≤4 Å 
bSA: Surface Area
Table 1: Suggested epitope motifs on the murine GPI dimer towards the paratope region of the 11H3 monoclonal antibody.
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are such “mirrored models” with high similarities to each other. Each 
of the ten top-ranking epitope models provided accessible surfaces 
larger than 1100 Å2, which is more than the average epitope surface 
of 650–1000 Å2 [58]. For the antigen-antibody complex consisting of 
the human GPI antigen and the 11H3 antibodies, the first ten epitope 
model predictions were likewise grouped after independent molecular 
docking (Supplemental Table 5).
In some of the epitope models of human GPI, the complete amino 
acid sequence was contributed by only one chain of the GPI dimer. 
The amino acid residues 134QR 138SGDWKGYTGKT 237S 240AK 261Q 
of epitope model 26, for instance, were located only on the A chain. 
“Mirror pairs” with human GPI are epitope models 20 and 21, 22 and 
23, as well as 24 and 25. These “mirror pairs” have identical sequence 
positions and amino acid residues.
As sequence homology between murine GPI and human GPI 
is approximately 89% and because both antibodies recognized both 
antigens in denatured form in a comparable fashion (Western blot data 
shown in Supplemental Figure 2), an inter-epitope species comparison 
was performed to identify those epitope models with best sequence 
similarities between the two species.
For example, the epitope model group that contained epitope models 
10 and 11 from the murine GPI-11H3 antibody pair matched closely with 
the sequence positions from the epitope model group that encompassed 
epitope models 20 and 21 from the human GPI-11H3 antibody pair. 
However, although the sequence positions in these cases were nearly 
identical, the respective amino acids at a given sequence position were 
not. By contrast, epitope model 14 from the murine GPI-11H3 antibody 
pair exhibited nearly identical amino acid positions and nearly identical 
amino acid residues as did epitope model 26 from the human GPI-11H3 
antibody pair. In both cases, the predicted epitope sequences were found 
on one and the same GPI amino acid chain without any contribution of 
the other chain of the GPI dimer. Consequently, epitope model 14 (bold 
print in Table 1) from the murine GPI-11H3 pair and epitope model 26 
(bold print in Supplemental Table 5) from the human GPI-11H3 pair 
were considered as best potential epitope candidates.
Docking calculations and sequence similarity analyses were 
performed identically for the complexes that consisted of the 46H9 
antibody Fv part bound to either the murine GPI or the human GPI 
dimer (Table 2 and Table S6). Here, epitope model 36 (bold print in 
Table 2) from the murine GPI-46H9 pair and epitope model 44 (bold 
print in Supplemental Table 6) from the human GPI-46H9 pair were 
considered best equivalents to each other, and hence, best epitope 
candidates. They provided similar consecutive sequence lengths and 
nearly identical amino acid sequences.
The best epitope models for either of the two monoclonal antibodies 
were visualized on the 3D structure of the GPI homodimer with epitope 
model 4 and 26, respectively, for 11H3 and epitope model 36 and 44, 
respectively, for 46H9 on either the murine GPI or the human GPI 
dimer (Figure 1). The visualized epitope model (partial sequences of 
model 14 in Table 1) of the 11H3 monoclonal antibody comprises 
aa134-148 (QRVRSGDWKGYTGKS) and aa232-241 (AAKDPSAVAK) 
on murine GPI, consisting of a helix-loop-helix motif that provides an 
assembled (conformational) epitope.
It should be noted that from all complexes of the murine GPI-
11H3 pair, epitope models 14, 15, 16, and 17 were located at nearly 
identical molecular surface regions (marked in blue in Figure 1) and 
epitope models 10, 11, 12, 13, 18, and 19 were located on different 
surface regions of the murine GPI dimer. Interestingly, all human GPI-
11H3 antibody complexes showed the 11H3 Fv component docked to 
one and the same surface region around the predicted epitope model 
(marked in blue in Figure 1) with only subtle differences. 
Comparably, the best epitope model of the 46H9 monoclonal 
antibody (partial sequence of epitope model 36 in Table 2), is located 
on the molecular surface of murine GPI comprising aa446-461 
(RKELQAAGKSPEDLEK), hence a consecutive (linear) epitope. 
All the murine GPI-46H9 complexes and all the human GPI-46H9 
complexes showed the 11H3 Fv component for all the 10 epitope 
models, each attached to one and the same surface region around the 
Epitope model Chain Epitope motifa SA [Å2]b
30
A 27R 30FEADP 438K 441L 444E 447K 841.78
B 524K 528E 534A 536TSHDS 543N 551.12
31
A 524K 536TSHDS 543N 427.35
B 16W 20N 23N 25K 27REL 31EADPER 60VSKE 438K 441L 443EE 447K 1631.42
32
A 176K 411Q 413QHPIRKG 481K 784.46
B 216Q 223E 226KE 230LE 234K 252K 255E 523K 526EP 530EGSS 550KQ 553RD 556K 1995.86
33
A 216Q 223E 226KE 230LE 234K 252K 254KE 523K 526EP 530EGSS 553RDTK 1904.15
B 176K 414HPIRKGL 424I 709.30
34
A 555TKL 341.17
B 45NTNH 106RSNT 123N 174Y 176K 291DH 294EQ 298SG 302W 305QH 309K 485F 1536.83
35
A 48H 106R 108N 127D 130K 134Q 137RS 173PYSK 288VG 291DH 294EQ 414H 481K 483T 1371.74
B 556KL 298.12
36
A 89K 95D 114DG 366K 478.89
B 450Q 453GKSPED 460EK 891.02
37
A 1MAA 6R 73KSRG 83N 89K 95D 114D 365TKSGAR 1334.61
B 446R 454KSPED 460EK 464P 869.46
38
A 536T 539DS 166.92
B 20N 23N 25K 27RELFEADPER 39N 62KE 66Q 443E 447K 1674.28
39
A - -
B 73KSRG 78EAARDN 85F 88S 109TP 112K 305Q 308LKTPL 366K 506D 1415.58
aDistance between epitope and paratope amino acid groups ≤4 Å
bSA: Surface Area
Table 2: Suggested epitope motifs on the murine GPI dimer towards the paratope region of the 46H9 monoclonal antibody.
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predicted epitope model (marked in red in Figure 1). Details of the 
predicted epitope-paratope interactions such as hydrogen bonding, 
salt bridges, ionic, cation-π, and hydrophobic [59-61] interactions have 
been summarized (Supplemental Tables 7-22). 
Most importantly, the predicted epitope models of the 11H3 and 
46H9 monoclonal antibodies are located distant from each other and 
do not share any surface regions (or partial sequences) on either murine 
GPI or human GPI. This observation is explained by the substantial 
differences in the amino acid sequences of the CDR regions, creating 
two completely different paratopes on the respective monoclonal 
antibodies.
Conformational mobility characterization of the epitope 
regions of the antibody-antigen complexes
According to the RMSD plot of the MD simulation trajectories 
of murine GPI antigen complexed with either monoclonal antibody 
11H3 or 46H9, the simulated antigen-antibody systems remained 
unchanged in both cases after 27 ns (data not shown). Hence, the 
last 15 ns of the 50 ns MD simulation trajectories were used for 
the calculation of positional flexibilities of backbone atoms of the 
murine GPI antigen in terms of alpha carbon root mean squared 
fluctuation (RMSF) as a function of amino acid position in the 
murine GPI sequence. The RMSF plot for murine GPI bound to the 
11H3 antibody (epitope model 14; dotted line in Figure 2) showed in 
general slightly higher flexibility as compared to the unbound murine 
GPI antigen (solid line). Most interestingly, upon antibody binding 
there was a slight decrease in flexibility at the amino acid regions 
aa130-150 and aa225-245, both of which are part of the predicted 
epitope model 14. This result stands in agreement with a reduction 
in conformational mobility of the amino acid residues of the epitope 
regions upon interaction with the paratope of the 11H3 antibody. By 
contrast, the slight decrease in flexibility at the N-terminal end upon 
antibody binding may simply be an artifact, as flexibility estimations 
of N-terminal and C-terminal tail regions are typically prone to 
erroneous outcomes.
Both RMSF plots of (i) murine GPI bound to the 46H9 antibody 
(epitope model 36; dotted line in Figure 3) and (ii) the unbound murine 
GPI (solid line) likewise showed regions of high and low flexibilities. Of 
note, the RMSF curve of bound murine GPI showed an offset towards 
higher flexibility as compared to the unbound murine GPI, since a 
different utility of the GROMACS software was used. Despite this offset, 
there was a significant decrease in flexibility at the amino acid region 
aa440-470, which encompassed the sequential epitope model 36, again 
indicating reduction in conformational mobility of the epitope region 
upon interaction with the paratope of the 46H9 antibody.
Estimation of key amino acid residues within the predicted 
epitopes
To estimate which of the amino acid residues of epitope model 14 
may play key roles in 11H3 antibody binding, relative binding energy 
changes between the murine GPI antigen and the 11H3 antibody upon 
site-specific exchanges of amino acid residues from the predicted 
epitope sequence were determined. The wild-type amino acid residues 
in the epitope model 14 sequence were assigned as reference (ΔGbind=0). 
Amino acid residues different from the wild-type amino acid residue at 
a given position on the epitope sequence with higher binding energies, 
i.e., positive ΔΔGbind values, were considered as having a destabilizing 
effect on the epitope-paratope interaction. By contrast, amino acid 
residues with negative ΔΔGbind values were considered as providing a 
stabilizing effect on the epitope-paratope interaction (Figure 4I).
Figure 1: Three-dimensional structures of GPI homodimers. A and C: Murine GPI (PDB ID 2CVP). B and D: Human GPI (PDB ID 1IRI). A and B: Molecular surfaces. 
Spheres indicate van-der-Waals radii of surface atoms. C and D: Cartoon views. Ribbons indicate locations of backbone atoms. The monomers are shown in green (A 
chain) and yellow (B chain). Blue: epitope region for monoclonal antibody 11H3. Red: Epitope region for monoclonal antibody 46H9.
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Figure 2: Positional flexibilities of backbone atoms of murine GPI (root mean squared fluctuation, RMSF) as a function of amino acid position in the amino acid sequence. 
Solid line: Unbound murine GPI. Dotted line: Murine GPI bound to antibody 11H3. A and B show zoomed regions around the partial sequences of the epitopes.
Figure 3: Positional flexibilities of backbone atoms of murine GPI (root mean squared fluctuation, RMSF) as a function of amino acid position in the amino acid sequence. 
Solid line: unbound murine GPI. Dotted line: Murine GPI bound to antibody 46H9. C shows a zoomed region around the partial sequence of the epitope.
In those cases when replacement of the wild-type amino acid 
residue by any other amino acid residue always yielded positive 
ΔΔGbind values (the respective column in Figure 4 starts above the 
“0” line), the respective wild-type amino acid residue (G146 on the 
left and K234, P236, and S237 on the right) was considered crucial for 
epitope-paratope interaction of the 11H3 antibody. The above analysis 
was identically performed for the murine GPI antigen complexed to 
the 46H9 antibody (epitope model 36). Here amino acid residues S455, 
P456, and E457 have been identified as important for binding the 46H9 
antibody (Figure 4II).
Validation of in silico epitope predictions by experimental 
data
The epitope peptide of the GPI-specific monoclonal antibody 11H3 
on the murine GPI antigen was confirmed by affinity mass spectrometry 
using peptide mixture I (Supplemental Table 23) that contained the 
11H3 epitope peptide and two standard peptides as controls. MALDI-
ToF MS analysis of peptide mixture I showed singly charged ion signals 
of the 11H3 epitope peptide and other standard peptides (Figure 5IA). 
The ion signal of the 11H3 epitope peptide was accompanied by an ion 
signal that indicated partial oxidation at the methionine residue.
Peptide mixture I was allowed to interact with the GPI-specific 
monoclonal antibody 11H3 as well as with the monoclonal antibody 
46H9, which served as a non-specific control. MALDI-ToF MS analysis 
of the eluted solutions showed the exclusive presence of an intense 
singly charged ion signal at m/z 3169.57 which corresponds to the 
11H3 epitope peptide when peptide mixture I was exposed to 11H3 
(Figure 5IB). Again an ion signal of the oxidized peptide was present, 
indicating that the methionine residue was not involved in antibody 
binding. By contrast, MALDI-ToF MS analysis of the eluted solution 
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Figure 4: I: Relative binding energy changes between the monoclonal antibody 11H3 and murine GPI upon site-specific exchange of amino acid residues. II: Relative 
binding energy changes between the monoclonal antibody 46H9 and murine GPI upon site-specific exchange of amino acid residues. Wild-type amino acid residues of 
the predicted epitope regions are shown at the bottom and are set to 0 kcal/mol (dotted line). Vertical bars show the ΔGbind binding energy ranges after point mutations. 
Mutated amino acid residues with the highest and the lowest ΔΔGbind values are represented above and below their respective bars for each epitope residue position. 
The horizontal lines (bold print) indicate continuous sequence stretches of the epitope amino acid residues.
Figure 5: MALDI-TOF mass spectra of peptide mixtures prior to and after epitope extraction. IA: Peptide mixture I. IB: Eluted peptides after epitope extraction using 
GPI-specific monoclonal antibody 11H3. The insert zooms into the monoisotopic pattern. IC: Eluted solution after exposing peptide mixture I to the 46H9 antibody (non-
specific control). For mass assignments of the 11H3 epitope extraction see table S23. IIA: Peptide mixture II. IIB: Eluted solution after exposure of peptide mixture II to the 
11H3 antibody (non-specific control). IIC: Eluted peptides after epitope extraction using GPI-specific monoclonal antibody 46H9. The insert zooms into the monoisotopic 
pattern. For mass assignments of the 46H9 epitope extraction see table S24. Ion signals are labelled. DHB was used as matrix.
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Figure 6: Cartoon view of the immune complex. A murine GPI dimer (yellow and green for A- and B-chain) is simultaneously decorated with GPI-specific monoclonal 
antibodies 46H9 (left) and 11H3 (right), showing the molecular dimensions of the antigen-antibody complexes. Red and violet: light chains. Blue and cyan: Heavy chains. 
The molecular dimensions of GPI are given (solid lines) and the distance of the Fc parts of the antibodies is indicated (dotted line).
after exposure of peptide mixture I to monoclonal antibody 46H9 
showed just baseline (Figure 5IC). None of the peptides in mixture I 
underwent strong interactions to this antibody.
The epitope confirmation of GPI-specific monoclonal antibody 
46H9 on murine GPI antigen was performed by affinity mass 
spectrometry using peptide mixture II (Supplemental Table 24) which 
consisted of five peptides spreading over the mass range of 1000 Da 
to 2500 Da. MALDI-ToF MS analysis of peptide mixture II showed 
singly charged ion signals of the 46H9 epitope peptide and the standard 
peptides (Figure 5IIA).
Peptide mixture II was then allowed to interact with the GPI-
specific monoclonal antibody 46H9 as well as with the monoclonal 
antibody 11H3, which was used as non-specific control. MALDI-ToF 
MS analysis of the eluted solution from the exposure of the peptide 
mixture to 11H3 showed the absence of peptide ion signals (Figure 
5IIB), i.e., no binding. By contrast, when peptide mixture II was exposed 
to 46H9, MALDI-ToF MS analysis (Figure 5IIC) of the eluted solution 
showed the presence of just one intense singly charged ion signal at m/z 
1799.10 which corresponds to the 46H9 epitope peptide. Hence, the 
experimental results stand in full agreement with the in silico predicted 
GPI epitopes.
Discussion
Since the recombinant GPI antigen is insoluble in non-denaturing 
buffers, computational prediction methods had to be chosen to 
approach the determination of the epitopes of the monoclonal 
antibodies 11H3 and 46H9. Predictions were verified with mass 
spectrometry-based epitope extraction [51,62,63] using synthetic 
peptides. The computational tools used for our predictions include the 
online Rosetta antibody server [39,56] for antibody modeling, and the 
ClusPro 2.0 server [57] for docking analyses. These computational tools 
were developed using many data sets and acceptable computational 
benchmarks. 
Of note, due to the large size of our proteins (1336 amino acid 
residues for the complex between GPI dimer and 46H9 antibody and 
1347 amino acid residues for the complex between GPI dimer and 11H3 
antibody), in silico mutations were performed on all the interfacial 
residues between the antigen (epitope) and antibody (paratope) 
complex using a simple, fast, and accurate tool, which depends on a set 
of statistical potentials derived from known protein structures [50,64] 
instead of using molecular mechanics/generalized Born surface area 
calculations (MM-GBSA) [65] and computational alanine scanning 
[66]. The epitopes of either the 11H3 or the 46H9 monoclonal antibodies 
on GPI contain surface-exposed loop regions, which is consistent with 
typical epitope features, such as being surface exposed [67], protruding 
from the surface of the antigen [68], and occurring in loops [69]. In 
addition, the presence of loop regions in our predicted epitopes agrees 
with the notion that protein-protein binding sites often occur at flexible 
protein regions [70].
Epitope determination, as performed by us, is important for 
understanding specific biological processes such as the recognition 
motifs involved in the disease initiation process. For example, 
biological activity of human CD20 monoclonal antibodies is linked to 
the unique epitopes on CD20 [71]. It has also been demonstrated that 
spatial arrangements of the secondary structural elements in epitope 
II on the hepatitis C virus E2 protein can determine how its specific 
antibody binds and ultimately directs the outcomes of either antibody-
mediated neutralization or non-neutralization [59]. The murine GPI 
antigen dimer structure extends from left to right by ~8.0 nm and from 
top to bottom by ~7.8 nm. Since the diameter of the Fab fragment of an 
antibody is normally between 1.6 nm and 2.3 nm [72], the murine GPI 
antigen provides sufficient area for simultaneous binding of two and 
even more GPI-specific monoclonal antibodies (Figure 6).
The GPI dimer can form multimeric complexes with the GPI-
specific monoclonal antibodies 11H3 and 46H9, and can appear as 
an opsonized antigen on the cartilage surface, cross-linking multiple 
Fragment Crystallizable Receptors (FcR) on cell surfaces, e.g. on 
macrophages. Such cross-linking events are necessary for the initiation 
of an inflammatory cascade [12,73]. On intact macrophage cells, FcR 
clusters with different sizes have been found using high-resolution 
Atomic Force Microscope (AFM) topography imaging with single-
molecule force spectroscopy [74]. The largest FcR clusters were greater 
than 200 nm in diameter (equivalent to ~15-50 FcRs), whereas smaller 
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clusters (micro-domains) were of 60-150 nm (equivalent to ~13-38 
FcRs) in size. Since macrophages have a diameter of 40-50 µm it can 
be estimated that one cell displays ~3,000 to 10,000 FcRs on its surface. 
The measured distance between the Fc parts of the two GPI-specific 
monoclonal antibodies 11H3 and 46H9 bound to natively folded 
murine GPI (Figure 6) is 30 nm and that of the Fc parts bound to 
completely unfolded (denatured) murine GPI is ~65 nm. In either case 
(native or denatured GPI) these distances are within the ranges that 
had been found for FcR distances of intact macrophages. Such compact 
clustering of the estimated FcRs on the surface of a macrophage cell 
likely will lead to either phagocytosis of murine GPI antigen-antiGPI 
antibody immune complexes and/or to the release of lytic enzymes and 
prostaglandins, which can initiate inflammation and, ultimately, lead 
to the destruction of cartilage matrix [75]. Additionally, the Fc part 
of the anti-GPI antibody, when bound to the GPI antigen, is able to 
covalently bind with the C3b complement protein, which is necessary 
to activate the alternative complement pathway. Complement protein 
C5a, resulting from this activation, interacts with C5a receptors which 
are expressed on neutrophils, macrophages and mast cells [76]. This 
process leads to production of pro-inflammatory cytokines, such as 
TNFα and IL-1 and also leads to the destruction of the joints [77]. 
Recently reported, transfer of monoclonal Anti-Citrullinated Protein/
Peptide Antibodies (ACPAs) into Balb/c mice also induced bone loss 
that was completely reversed by the IL-8 antagonist reparixin [78]. 
From this study, IL-8 has been identified as a chemokine-dependent 
molecular mechanism underlying Rheumatoid Arthritis-associated 
autoantibody-mediated bone loss.
Epitope determination of the pathogenic GPI-specific monoclonal 
antibodies on the GPI autoantigen eventually leads to the synthesis 
of epitope-derived peptides that may be used for improved disease 
diagnosis using peptide-based diagnostic techniques [79]. Epitope-
derived peptides can also be envisaged to find use as vaccines for 
patient therapy, as demonstrated in cancer treatment [80]. The epitope 
peptides will also be useful for generating anti-anti-GPI-specific anti-
idiotypic antibodies from IVIg preparations [81], which can be used for 
treatment of arthritis in the K/BxN mouse model and subsequently for 
targeting GPI-specific autoantibodies in RA patients. Knowledge of the 
epitopes of GPI-specific monoclonal antibodies 11H3 and 46H9 paves 
the way for understanding the principle of function for disease onset 
processes in the K/BxN mouse disease at the molecular level.
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